Overview Radotinib as 3rd or Later Line Therapy in CP-CML Status: Unknown status Trial end date: 2019-03-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors. Phase: Phase 2 Details Lead Sponsor: Ulsan University Hospital